ArticleCancer immunology, immunotherapy : CII2017

Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.

Andrew Zloza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.